Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1751P - Real-world study of REarranged during Transfection [RET] testing in patients [pts] with medullary thyroid cancer [MTC] in Europe [EU5]

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Thyroid Cancer

Presenters

Rhys Williams

Citation

Annals of Oncology (2021) 32 (suppl_5): S1205-S1210. 10.1016/annonc/annonc715

Authors

R. Williams1, L.M. Hess2, T. Puri2, M. Jen2, M. Kostikas1, A. Rider1, U. Kiiskinen2

Author affiliations

  • 1 Adelphi Real World, Adelphi Group, SK10 5JB - Bollington/GB
  • 2 Health Outcomes, Eli Lilly and Company, IN46225 - Indianapolis/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1751P

Background

This study described testing for mutations in the RET gene among pts with sporadic and hereditary MTC, a crucial factor in selecting targeted therapy linked with improved treatment [tx] outcomes for pts with MTC.

Methods

Real-world data were drawn from the Adelphi Thyroid Cancer Disease Specific ProgrammeTM – a point-in-time survey conducted July-December 2020 primarily with medical oncologists and endocrinologists in clinical practice. Physicians in France [FR], Germany [DE], Italy [IT], Spain [ES] and the UK completed patient record forms for the next 4 consulting adult MTC pts, providing demographics and testing patterns.

Results

153 physicians (70% medical oncologists, 20% endocrinologists) provided data on 275 pts. 207 (75%) pts were tested for any RET gene mutation, of these 79 (38%) were positive. 91 (44%) were tested for both germline and somatic mutation, 73 (35%) for germline mutation, 43 (21%) for somatic mutation at any time; mean (SD) time to get results was 20.2 (15.6) days. 140 (68%) were tested post MTC diagnosis, 85 (41%) were tested before tx initiation. When tested, 69 (33%) had a known disease state, of which 50 (72%) had locally advanced or metastatic disease. 207 pts received on average 0.9 and 1.0 tests in the 12 months prior to data abstraction for germline and somatic RET gene mutations respectively. Data were captured for 203 tests. Polymerase chain reaction (PCR) (35%) and next generation sequencing (NGS) (30%) were most common methods used. Use of PCR and NGS varied across countries (PCR: ES 43%, UK 22%, NGS: UK 61%, ES 7%). Across all tests, tissue (51%) and blood (44%) were most frequent samples. 132 (86%) physicians reported testing pts for any RET gene mutations; highest among endocrinologists 29 (97%). Greatest barrier to RET gene testing cited was delay in getting results (26%) across EU5; in DE, cost (25%) and UK guideline restrictions (27%) were most cited.

Conclusions

Most physicians request a RET gene test for their pts with MTC. With the advent of increasingly individualised regimens, there remains a need to broaden RET gene testing amongst pts at diagnosis, during localised disease status, and prior to tx initiation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Adelphi Group.

Funding

Adelphi Group.

Disclosure

R. Williams: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. L.M. Hess: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. T. Puri: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. M. Jen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. M. Kostikas: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. A. Rider: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. U. Kiiskinen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.